Shareholders of Copenhagen-based research institute Nuevolution accepted a $167 million takeover bid from Amgen, the Thousand Oaks biotech heavyweight announced June 8. Amgen made the offer May 22, valuing the stock at around $3.37 per share, more than twice its May 21 closing price on the Nasdaq Stockholm exchange. Additionally, Amgen agreed to purchase another…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
